J
Jiri Minarik
Researcher at Palacký University, Olomouc
Publications - 99
Citations - 1267
Jiri Minarik is an academic researcher from Palacký University, Olomouc. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 12, co-authored 75 publications receiving 874 citations. Previous affiliations of Jiri Minarik include Masaryk University.
Papers
More filters
Journal ArticleDOI
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal,Paul G. Richardson,S. Vincent Rajkumar,Jesús F. San-Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Sandrine Macé,Kathryn P. Corzo,Frank Campana,Solenn Le-Guennec,Franck Dubin,Kenneth C. Anderson,Vincent Rajkumar,Simon J. Harrison,Wojt Janowski,Ian Kerridge,Andrew Spencer,Michel Delforge,Karel Fostier,Philip Vlummens,Ka Lung Wu,Richard Leblanc,Michel Pavic,Michael Sebag,Roman Hájek,Vladimir Maisnar,Ludek Pour,Henrik Gregersen,Lotfi Benbouker,Denis Caillot,Martine Escoffre-Barbe,Thierry Facon,Laurent Frenzel,Cyrille Hulin,Lionel Karlin,Brigitte Kolb,Brigitte Pegourie,Aurore Perrot,Mourad Tiab,Laure Vincent,Dietger Niederwieser,Achilles Anagnostopoulos,Sosana Delimpasi,Marie Christine Kyrtsonis,Anargyros Symeonidis,Árpád Illés,Gabor Mikala,Zsolt Nagy,Sara Bringen,Paolo Corradini,Ciceri Fabio,Roberto M. Lemoli,Anna Marina Liberati,Chiara Nozzoli,Renato Zambello,Shinsuke Iida,Takashi Ikeda,Satoshi Iyama,Morio Matsumoto,Chihiro Shimazaki,Kazutaka Sunami,Kenshi Suzuki,Michihiro Uchiyama,Youngil Koh,Ki-Hyun Kim,Jae Hoon Lee,Chang-Ki Min,Hillary Blacklock,Hugh Goodman,AJ Neylon,David Simpson,Sebastian Grosicki,Artur Jurczyszyn,Adam Walter-Croneck,Krzysztof Warzocha,Luis Araujo,Claudia Moreira,Vadim A Doronin,Larisa P. Mendeleeva,Vladimir I. Vorobyev,Andrej Vranovsky,Adrian Alegre,Mercedes Gironella,Marta Sonia Gonzalez Perez,Carmen Montes,Enrique M. Ocio,Paula Rodriguez,Mats Hardling,Birgitta Lauri,Ming Chung Wang,Su Peng Yeh,Mutlu Arat,Fatih Demirkan,Zafer Gulbas,Sevgi Kalayoglu Besisik,Ihsan Karadogan,Tulin Tuglular,Ali Ünal,Filiz Vural,Jonathan Sive,Matthew Streetly,Kwee Yong,Jason Tache +111 more
TL;DR: The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomidine and dexAMethas one in patients with relapsed and refractory multiple myeloma.
Journal ArticleDOI
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Hervé Avet-Loiseau,Rafael Fonseca,David A. Siegel,Meletios A. Dimopoulos,Ivan Spicka,Tamas Masszi,Roman Hájek,Laura Rosiñol,Vesselina Goranova-Marinova,Georgi Mihaylov,Vladimir Maisnar,Maria-Victoria Mateos,Michael Wang,Ruben Niesvizky,Albert Oriol,Andrzej Jakubowiak,Jiri Minarik,Antonio Palumbo,William I. Bensinger,Vishal Kukreti,Dina Ben-Yehuda,A. Keith Stewart,Mihaela Obreja,Philippe Moreau +23 more
TL;DR: This regimen had a favorable benefit-risk profile in patients with relapsed MM, irrespective of cytogenetic risk status, and should be considered a standard of care in these patients.
Journal ArticleDOI
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
Roman Hájek,Tamás Masszi,M.T. Petrucci,Antonio Palumbo,Laura Rosiñol,Arnon Nagler,Kwee Yong,Albert Oriol,Jiri Minarik,Luděk Pour,Meletios A. Dimopoulos,Vladimir Maisnar,Davide Rossi,H. Kasparu,J. Van Droogenbroeck,Dina Ben Yehuda,Izhar Hardan,Matthew W Jenner,M. Calbecka,M. Dávid,J de la Rubia,Johannes Drach,Z. Gasztonyi,S. Górnik,Xavier Leleu,Markus Munder,Massimo Offidani,Niklas Zojer,Kanya Rajangam,Y.-L. Chang,Jesús F. San-Miguel,Heinz Ludwig +31 more
TL;DR: Median OS for single-agent carfilzomib was similar to that for an active doublet control regimen in heavily pretreated RRMM patients, and overall response rate was higher with carfilZomib than with control.
Journal ArticleDOI
Extramedullary disease in multiple myeloma - controversies and future directions.
TL;DR: Current knowledge aboutExtramedullary disease of multiple myeloma is summarized, including its history, diagnostics, imaging methods, incidence, prognosis, current treatment options, risk factors and known molecular mechanisms that might be involved in pathogenesis of EM.
Journal ArticleDOI
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Jiri Minarik,Petr Pavlicek,Ludek Pour,Tomas Pika,Vladimir Maisnar,Ivan Spicka,Jiri Jarkovsky,Marta Krejčí,Jaroslav Bacovsky,Jakub Radocha,Jan Straub,Petr Kessler,Marek Wrobel,L. Walterová,Michal Sykora,Jarmila Obernauerova,Lucie Brozova,Evzen Gregora,Dagmar Adamova,J. Gumulec,Zdenek Adam,Vlastimil Scudla,Roman Hájek +22 more
TL;DR: Subcutaneous application of bortezomib has similar therapeutic outcomes and toxicity profile as intravenous route of application, and there was no difference in the incidence of PN, suggesting that PN is dose dependent and might be reduced by lower intensity schemes rather than by the route of administration.